Transformative deal targets the biological roots of autism, opening a new frontier in disease-modifying therapy.
XTL Biopharmaceuticals has taken a decisive step into one of the most urgent and underserved areas of modern medicine by signing a binding agreement to acquire 85% of NeuroNOS Ltd., a biotechnology company focused on disease-modifying treatments for Autism Spectrum Disorder (ASD) and neuro-oncology. The transaction, announced in January, positions XTL at the forefront of a rapidly expanding autism therapeutics market, where no approved therapies currently address the biological drivers of the condition.
Unlike existing treatments that focus only on managing behavioral symptoms, NeuroNOS is developing therapies designed to target the core molecular and neurological mechanisms underlying autism. This approach aims to modify the disease itself, rather than simply mitigating its outward effects, offering the possibility of fundamentally changing outcomes for patients and families.
Beyond Air, NeuroNOS’s parent company, will retain a 19.99% ownership stake in XTL following the transaction and is eligible to receive up to $32.5 million in upfront, development, and commercial milestone payments. The structure reflects both companies’ confidence in the long-term value of NeuroNOS’s platform while aligning incentives for clinical and commercial success.
The timing of the acquisition is notable. Autism now affects approximately one in 31 children in the United States, a staggering increase that has placed immense pressure on healthcare systems, schools, and families. Despite decades of research, no FDA-approved therapies currently exist to alter the biological course of autism, leaving a massive unmet medical need.
Public policy attention is also intensifying. Recent statements from U.S. leadership have underscored autism as a growing public health crisis, increasing the likelihood of regulatory, funding, and research support for innovative solutions.
By acquiring NeuroNOS, XTL is not simply expanding its pipeline — it is entering a market with profound social, medical, and economic impact. If NeuroNOS’s science delivers on its promise, the company could help redefine how autism is treated, moving the field beyond symptom management toward true disease modification.
You might like this article:Google Joins the $4 Trillion Club as AI Boom Rewrites Big Tech’s Power Rankings
